Answers are grounded in this paper and cite their sources.
Cyclin-dependent kinase inhibitor 2 A ( CDKN2A ) dysregulation is a recurrent and biologically significant event across a wide spectrum of haematological malignancies, contributing to disease initiation, progression, and therapeutic resistance. This manuscript provides a comprehensive review of genetic and epigenetic mechanisms underlying CDKN2A disruption in blood cancers and selected haematologic neoplasms. We summarise evidence for copy number loss, promoter hypermethylation, and regulatory silencing as dominant modes of CDKN2A inactivation, and highlight how these alterations intersect with aberrant cell-cycle control. Particular attention is given to the clinical relevance of CDKN2A dysregulation as a prognostic marker and its association with adverse outcomes and treatment refractoriness. Finally, we review evolving therapeutic strategies aimed at restoring CDKN2A pathway activity, including genome- and epigenome-editing platforms and immune-based approaches. Collectively, this work underscores the central role of CDKN2A dysregulation in haematological malignancies and supports its continued investigation as both a biomarker and a therapeutic vulnerability in precision oncology.
No takes yet. Share an insight, caveat, or question.
Mazlan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: